ArticleFrontiers in cellular and infection microbiology2019
Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease.
Article in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 4 syntheses or guidelines pooled it, 276 citations in OpenAlex.
- Gut Microbiome in Patients with Chronic Kidney Disease Stages 4 and 5: A Systematic Literature Review.International journal of molecular sciences · 2025Pooled it
- Gut Microbiome Characteristics in IgA Nephropathy: Qualitative and Quantitative Analysis from Observational Studies.Frontiers in cellular and infection microbiology · 2022Pooled it
- Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review.Renal failure · 2021Pooled it
- The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature.BMC nephrology · 2020Pooled it
- Trial
- Gut microbiota biomarkers of chronic kidney disease progression identified by 16S rDNA sequencing and machine learning.Renal failure · 2026Article
- Lactobacillus and Tryptophan Supplementation Improve Renal Function and are Associated with Metabolomic Alterations in a Mouse Model of Chronic Kidney Disease.Probiotics and antimicrobial proteins · 2026Article
- Risk factors and prediction model of renal dysfunction in patients with inflammatory bowel disease: a retrospective cohort study.BMC gastroenterology · 2026Article
- Analysis of Gut Microbiota Metabolites in Chronic Kidney Disease-Associated Pruritus Using Network Pharmacology and Molecular Docking.Iranian journal of biotechnology · 2026Article
- A spotlight on the inflammatory role of uremic toxins in the dysbiosis-CKD axis: a review.Journal of inflammation (London, England) · 2026Review
- Protecting Kidney Health in the First 1000 Days: The Pediatrician's Role in Safeguarding the Weakest.Diseases (Basel, Switzerland) · 2026Review
- Consequences of Western and Mediterranean Diets' Nutrients on the Microbiota-Gut-Brain Axis.Nutrients · 2026Review
- Lactulose, a Disaccharide Prebiotic, Improves the Gut-Kidney Axis via Enhancement of Akkermansia Muciniphila Production.Kidney360 · 2026Article
- Metabolic Dysfunction-associated Steatotic Liver Disease and Chronic Kidney Disease: From Epidemiology and Pathophysiology to Clinical Prediction and Treatment Options.Journal of clinical and translational hepatology · 2026Review
- Akkermansia muciniphila confers renal protection in chronic kidney disease: a multi-omics mechanistic investigation.BMC microbiology · 2026Article
- Corn silk ameliorates fatty liver disease by modulating the gut microbiota and metabolites in the serum and liver.Scientific reports · 2026Article
- Time-dependent Lactiplantibacillus plantarum (LP) AS21 intervention enhances mesalazine efficacy by modulating gut microbiota and host immunometabolic responses in DSS-induced colitis.Journal of translational medicine · 2026Article
- Gut-Kidney Axis: Unraveling the Role of the Microbiome in Chronic Kidney Disease.Biomedicines · 2026Review
- Microbes and GFR in Health and CKD in Mice.Journal of the American Society of Nephrology : JASN · 2026Article
- Therapeutic potential and research progress of microecological agents in kidney diseases.Frontiers in medicine · 2026Review
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations to the gut microbiota have been previously suggested to be tightly linked to chronic systemic inflammation, which is a major contributing factor to complications and disease progression in chronic kidney disease (CKD). Nevertheless, the effect of gut dysbiosis on the pathogenesis and/or production of inflammatory factors in CKD has not been extensively studied to date. In the present study, we conducted 16S ribosomal DNA pyrosequencing using fecal microbiota samples and analyzed the production of serum inflammatory factors in 50 patients with CKD and 22 healthy control (HC) subjects. The results revealed that compared to the HC subjects, patients with CKD exhibited a significant reduction in the richness and structure of their fecal microbiota. At the phylum level, compared to the HC group, patients with CKD also presented reduced abundance of Actinobacteria but increased abundance of Verrucomicrobia. Moreover, the genera
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.